<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM"><PMID Version="2">31376190</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>272</StartPage><EndPage>282</EndPage><MedlinePgn>272-282</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.12774</ELocationID><Abstract><AbstractText>Muscle weakness plays an important role in neuromuscular disorders comprising amyotrophic lateral sclerosis (ALS). However, it is not established whether muscle denervation originates from the motor neurons, the muscles or more likely both. Previous studies have shown that the expression of the SOD1G93A mutation in skeletal muscles causes denervation of the neuromuscular junctions, inability to regenerate and consequent atrophy, all clear symptoms of ALS. In this work, we used SOD1G93A mice, a model that best mimics some pathological features of both familial and sporadic ALS, and we investigated some biological effects induced by the activation of the P2X7 receptor in the skeletal muscles. The P2X7, belonging to the ionotropic family of purinergic receptors for extracellular ATP, is abundantly expressed in the healthy skeletal muscles, where it controls cell duplication, differentiation, regeneration or death. In particular, we evaluated whether an in vivo treatment in SOD1G93A mice with the P2X7 specific agonist 2'(3')-O-(4-Benzoylbenzoyl) adenosine5'-triphosphate (BzATP) just before the onset of a pathological neuromuscular phenotype could exert beneficial effects in the skeletal muscles. Our findings indicate that stimulation of P2X7 improves the innervation and metabolism of myofibers, moreover elicits the proliferation/differentiation of satellite cells, thus preventing the denervation atrophy of skeletal muscles in SOD1G93A mice. Overall, this study suggests that a P2X7-targeted and site-specific modulation might be a strategy to interfere with the complex multifactorial and multisystem nature of ALS.</AbstractText><CopyrightInformation>&#xa9; 2019 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fabbrizio</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apolloni</LastName><ForeName>Savina</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvatori</LastName><ForeName>Illari</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valle</LastName><ForeName>Cristiana</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Research Council, Institute of Translational Pharmacology, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanzuolo</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Research Council, Institute of Biomedical Technologies, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bendotti</LastName><ForeName>Caterina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardo</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1803-1484</Identifier><AffiliationInfo><Affiliation>Laboratory of Molecular Neurobiology, Department of Neuroscience, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volont&#xe9;</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7362-8307</Identifier><AffiliationInfo><Affiliation>IRCCS Fondazione Santa Lucia, Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Research Council, Institute for Systems Analysis and Computer Science, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546469">P2rx7 protein, mouse</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058486">Receptors, Purinergic P2X7</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="C109415">SOD1 G93A protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009469" MajorTopicYN="N">Neuromuscular Junction</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058486" MajorTopicYN="N">Receptors, Purinergic P2X7</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SOD1G93A mice</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">purinergic receptors</Keyword><Keyword MajorTopicYN="N">skeletal muscle</Keyword></KeywordList><CoiStatement>The authors have no competing financial interests to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31376190</ArticleId><ArticleId IdType="pmc">PMC7065186</ArticleId><ArticleId IdType="doi">10.1111/bpa.12774</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Almada AE, Wagers AJ (2016) Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease. Nat Rev Mol Cell Biol 17:267&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4918817</ArticleId><ArticleId IdType="pubmed">26956195</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Montilli C, Volonte C, D&#x2019;Ambrosi N (2013) Ablation of P2X7 receptor exacerbates gliosis and motoneuron death in the SOD1&#x2010;G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet 22:4102&#x2013;4116.</Citation><ArticleIdList><ArticleId IdType="pubmed">23736299</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Amadio S, Parisi C, Matteucci A, Potenza RL, Armida M et al (2014) Spinal cord pathology is ameliorated by P2X7 antagonism in a SOD1&#x2010;mutant mouse model of amyotrophic lateral sclerosis. Dis Model Mech 7:1101&#x2013;1109.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142730</ArticleId><ArticleId IdType="pubmed">25038061</ArticleId></ArticleIdList></Reference><Reference><Citation>Apolloni S, Parisi C, Pesaresi MG, Rossi S, Carri MT, Cozzolino M et al (2013) The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1&#x2010;G93A microglia model of amyotrophic lateral sclerosis. J Immunol 190:5187&#x2013;5195.</Citation><ArticleIdList><ArticleId IdType="pubmed">23589615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett R, Sluyter V, Watson D, Sluyter R, Yerbury JJ (2017) P2X7 antagonism using Brilliant Blue G reduces body weight loss and prolongs survival in female SOD1 G93A amyotrophic lateral sclerosis mice. PeerJ 5:e3064.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5335685</ArticleId><ArticleId IdType="pubmed">28265522</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnstock G (2017) Purinergic signalling: therapeutic developments. Front Pharmacol 8:661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5622197</ArticleId><ArticleId IdType="pubmed">28993732</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanari M&#x2010;L, Garc&#xed;a&#x2010;Ayll&#xf3;n M&#x2010;S, Ciura S, S&#xe1;ez&#x2010;Valero J, Kabashi E (2016) Neuromuscular junction impairment in amyotrophic lateral sclerosis: reassessing the role of acetylcholinesterase. Front Mol Neurosci 9:160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5187284</ArticleId><ArticleId IdType="pubmed">28082868</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener 13:8&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Deuchars SA, Atkinson L, Brooke RE, Musa H, Milligan CJ, Batten TFC et al (2001) Neuronal P2X 7 receptors are targeted to presynaptic terminals in the central and peripheral nervous systems. J Neurosci 21:7143&#x2013;7152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6762981</ArticleId><ArticleId IdType="pubmed">11549725</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolny G, Lepore E, Martini M, Barberi L, Nunn A, Scicchitano BM, Musar&#xf2; A (2018) Metabolic changes associated with muscle expression of SOD1G93A. Front Physiol 9:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6048270</ArticleId><ArticleId IdType="pubmed">30042688</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabbrizio P, Amadio S, Apolloni S, Volont&#xe9; C (2017) P2X7 receptor activation modulates autophagy in SOD1&#x2010;G93A mouse microglia. Front Cell Neurosci 11:249.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5566572</ArticleId><ArticleId IdType="pubmed">28871219</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, Coccurello R (2017) What is &#x201c;hyper&#x201d; in the ALS hypermetabolism? Mediators Inflamm 2017:1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5610793</ArticleId><ArticleId IdType="pubmed">29081604</ArticleId></ArticleIdList></Reference><Reference><Citation>Francetic T, Li Q (2011) Skeletal myogenesis and Myf5 activation. Transcription 2:109&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3173648</ArticleId><ArticleId IdType="pubmed">21922054</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xf3;recki DC (2019) P2X7 purinoceptor as a therapeutic target in muscular dystrophies. Curr Opin Pharmacol 47:40&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">30901735</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones RA, Reich CD, Dissanayake KN, Kristmundsdottir F, Findlater GS, Ribchester RR et al (2016) NMJ&#x2010;morph reveals principal components of synaptic morphology influencing structure&#x2014;function relationships at the neuromuscular junction. Open Biol 6:160240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5204123</ArticleId><ArticleId IdType="pubmed">27927794</ArticleId></ArticleIdList></Reference><Reference><Citation>Juaristi I, Llorente&#x2010;Folch I, Satr&#xfa;stegui J, del Arco A (2019) Extracellular ATP and glutamate drive pyruvate production and energy demand to regulate mitochondrial respiration in astrocytes. Glia 67:759&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">30623988</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovanda A, Leonardis L, Zidar J, Koritnik B, Dolenc&#x2010;Groselj L, Ristic Kovacic S et al (2018) Differential expression of microRNAs and other small RNAs in muscle tissue of patients with ALS and healthy age&#x2010;matched controls. Sci Rep 8:5609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884852</ArticleId><ArticleId IdType="pubmed">29618798</ArticleId></ArticleIdList></Reference><Reference><Citation>Krasnianski A, Deschauer M, Neudecker S, Gellerich FN, M&#xfc;ller T, Schoser BG et al (2005) Mitochondrial changes in skeletal muscle in amyotrophic lateral sclerosis and other neurogenic atrophies. Brain 128:1870&#x2013;1876.</Citation><ArticleIdList><ArticleId IdType="pubmed">15901649</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler JP, Picchiarelli G, Dupuis L, Gonzalez De Aguilar JL (2016) The role of skeletal muscle in amyotrophic lateral sclerosis. Brain Pathol 26:227&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029271</ArticleId><ArticleId IdType="pubmed">26780251</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo G, Yi J, Ma C, Xiao Y, Yi F, Yu T, Zhou J (2013) Defective mitochondrial dynamics is an early event in skeletal muscle of an amyotrophic lateral sclerosis mouse model. PLoS One 8:e82112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855744</ArticleId><ArticleId IdType="pubmed">24324755</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinello T, Baldoin MC, Morbiato L, Paganin M, Tarricone E, Schiavo G et al (2011) Extracellular ATP signaling during differentiation of C2C12 skeletal muscle cells: role in proliferation. Mol Cell Biochem 351:183&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pubmed">21308481</ArticleId></ArticleIdList></Reference><Reference><Citation>Mauro A (1961) Satellite cell of skeletal muscle fibers. J Cell Biol 9:493&#x2013;495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2225012</ArticleId><ArticleId IdType="pubmed">13768451</ArticleId></ArticleIdList></Reference><Reference><Citation>Miteva AS, Gaydukov AE, Shestopalov VI, Balezina OP (2018) Mechanism of P2X7 receptor&#x2010;dependent enhancement of neuromuscular transmission in pannexin 1 knockout mice. Purinergic Signal 14:459&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298918</ArticleId><ArticleId IdType="pubmed">30362043</ArticleId></ArticleIdList></Reference><Reference><Citation>Moores TS, Hasdemir B, Deuchars J, Parson SH (2005) Properties of presynaptic P2X 7 &#x2010;like receptors at the neuromuscular junction. Brain Res 1034:40&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">15713258</ArticleId></ArticleIdList></Reference><Reference><Citation>Myoung JC, Suh YL (2002) Ultrastructural changes of mitochondria in the skeletal muscle of patients with amyotrophic lateral sclerosis. Ultrastruct Pathol 26:3&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12028652</ArticleId></ArticleIdList></Reference><Reference><Citation>Nardo G, Trolese MC, Verderio M, Mariani A, de Paola M, Riva N et al (2018) Counteracting roles of MHCI and CD8+ T cells in the peripheral and central nervous system of ALS SOD1G93A mice. Mol Neurodegener 13:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6085701</ArticleId><ArticleId IdType="pubmed">30092791</ArticleId></ArticleIdList></Reference><Reference><Citation>Nijssen J, Comley LH, Hedlund E (2017) Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol 133:863&#x2013;885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5427160</ArticleId><ArticleId IdType="pubmed">28409282</ArticleId></ArticleIdList></Reference><Reference><Citation>Parisi C, Arisi I, D&#x2019;Ambrosi N, Storti AE, Brandi R, D&#x2019;Onofrio M, Volont&#xe9; C (2013) Dysregulated microRNAs in amyotrophic lateral sclerosis microglia modulate genes linked to neuroinflammation. Cell Death Dis 4:e959.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877562</ArticleId><ArticleId IdType="pubmed">24336079</ArticleId></ArticleIdList></Reference><Reference><Citation>Philips T, Rothstein JD (2015) Rodent models of amyotrophic lateral sclerosis. Curr Protoc Pharmacol 69:5.67.1&#x2013;5.67.21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4562058</ArticleId><ArticleId IdType="pubmed">26344214</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues RJ, Marques JM, Cunha RA (2018) Purinergic signalling and brain development. Semin Cell Dev Biol pii: S1084&#x2010;9521(18)30065&#x2010;X.</Citation></Reference><Reference><Citation>Scaramozza A, Marchese V, Papa V, Salaroli R, Sorar&#xf9; G, Angelini C, Cenacchi G (2014) Skeletal muscle satellite cells in amyotrophic lateral sclerosis. Ultrastruct Pathol 38:295&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">25079897</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith EF, Shaw PJ, De Vos KJ (2017) The role of mitochondria in amyotrophic lateral sclerosis. Neurosci Lett pii: S0304&#x2010;3940(17)30544&#x2010;X.</Citation></Reference><Reference><Citation>Song X, Xu X, Zhu J, Guo Z, Li J, He C et al (2015) Up&#x2010;regulation of P2X7 receptors mediating proliferation of Schwann cells after sciatic nerve injury. Purinergic Signal 11:203&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4425717</ArticleId><ArticleId IdType="pubmed">25682129</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperl&#xe1;gh B, Illes P (2014) P2X7 receptor: an emerging target in central nervous system diseases. Trends Pharmacol Sci 35:537&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pubmed">25223574</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk Kim M, Lee J, Ha J, Soo Kim S, Kong Y, Ho Cho Y et al (2002) ATP stimulates glucose transport through activation of P2 purinergic receptors in C2C12 skeletal muscle cells. Arch Biochem Biophys 401:205&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pubmed">12054471</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarasov AI, Griffiths EJ, Rutter GA (2012) Regulation of ATP production by mitochondrial Ca2+ . Cell Calcium 52:28&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396849</ArticleId><ArticleId IdType="pubmed">22502861</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsitkanou S, Gatta PAD, Russell AP (2016) Skeletal muscle satellite cells, mitochondria, and MicroRNAs: their involvement in the pathogenesis of ALS. Front Physiol 7:403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5020084</ArticleId><ArticleId IdType="pubmed">27679581</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Virgilio F, Dal Ben D, Sarti AC, Giuliani AL, Falzoni S (2017) The P2X7 receptor in Infection and Inflammation. Immunity 47:15&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">28723547</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, Amadio S, D&#x2019;Ambrosi N, Colpi M, Burnstock G (2006) P2 receptor web: complexity and fine&#x2010;tuning. Pharmacol Ther 112:264&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">16780954</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Apolloni S, D. Skaper S, Burnstock G, (2012) P2X7 Receptors: Channels, Pores and More. CNS Neurol Disord &#x2010; Drug Targets 11(6):705&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pubmed">22963440</ArticleId></ArticleIdList></Reference><Reference><Citation>Volonte C, Apolloni S, Parisi C (2015) MicroRNAs: newcomers into the ALS picture. CNS Neurol Disord &#x2010; Drug Targets 14:194&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">25613506</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, Apolloni S, Parisi C, Amadio S (2016) Purinergic contribution to amyotrophic lateral sclerosis. Neuropharmacology 104:180&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pubmed">26514402</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, D&#x2019;Ambrosi N (2009) Membrane compartments and purinergic signalling: the purinome, a complex interplay among ligands, degrading enzymes, receptors and transporters. FEBS J 276:318&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">19076212</ArticleId></ArticleIdList></Reference><Reference><Citation>Volont&#xe9; C, Parisi C, Apolloni S (2015) New kid on the block: does histamine get along with inflammation in amyotrophic lateral sclerosis? CNS Neurol Disord Drug Targets 14:677&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">25714965</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vos KJ, Hafezparast M (2017) Neurobiology of axonal transport defects in motor neuron diseases: opportunities for translational research? Neurobiol Dis 105:283&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5536153</ArticleId><ArticleId IdType="pubmed">28235672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jaenisch R (1997) Myogenin can substitute for Myf5 in promoting myogenesis but less efficiently. Development 124:2507&#x2013;2513.</Citation><ArticleIdList><ArticleId IdType="pubmed">9216993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jaenisch R (1997) Myogenin can substitute for Myf5 in promoting myogenesis but less efficiently. Development 124:2507&#x2013;2513.</Citation><ArticleIdList><ArticleId IdType="pubmed">9216993</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin H, Price F, Rudnicki MA (2013) Satellite cells and the muscle stem cell niche. Physiol Rev 93:23&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4073943</ArticleId><ArticleId IdType="pubmed">23303905</ArticleId></ArticleIdList></Reference><Reference><Citation>Young CNJ, Sinadinos A, Gorecki DC (2013) P2X receptor signaling in skeletal muscle health and disease. WIREs Membr Transp Signal 2:265&#x2013;274.</Citation></Reference><Reference><Citation>Young CNJ, Sinadinos A, Lefebvre A, Chan P, Arkle S, Vaudry D, Gorecki DC (2015) A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large&#x2010;pore formation and HSP90. Autophagy 11:113&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502824</ArticleId><ArticleId IdType="pubmed">25700737</ArticleId></ArticleIdList></Reference><Reference><Citation>Zammit PS, Golding JP, Nagata Y, Hudon V, Partridge TA, Beauchamp JR (2004) Muscle satellite cells adopt divergent fates. J Cell Biol 166:347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172269</ArticleId><ArticleId IdType="pubmed">15277541</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>